Methoplain en es it fr

Methoplain Brand names, Methoplain Analogs

Methoplain Brand Names Mixture

  • No information avaliable

Methoplain Chemical_Formula


Methoplain RX_link

Methoplain fda sheet

Methoplain FDA

Methoplain msds (material safety sheet)

Methoplain MSDS

Methoplain Synthesis Reference

No information avaliable

Methoplain Molecular Weight

1270.28 g/mol

Methoplain Melting Point

No information avaliable

Methoplain H2O Solubility

Freely soluble as sodium salt (> 200mg/mL)

Methoplain State


Methoplain LogP

No information avaliable

Methoplain Dosage Forms

Powder for solution (for injection)

Methoplain Indication

For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Methoplain Pharmacology

Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.

Methoplain Absorption

No information avaliable

Methoplain side effects and Toxicity

Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.

Methoplain Patient Information

No information avaliable

Methoplain Organisms Affected

Aspergillis, Candida and other fungi